TY - JOUR
T1 - Joint Associations of Pregnancy Complications and Postpartum Maternal Renal Biomarkers With Severe Cardiovascular Morbidities
T2 - A US Racially and Ethnically Diverse Prospective Birth Cohort Study
AU - Hong, Xiumei
AU - Rosenberg, Avi Z.
AU - Heymann, Jurgen
AU - Yoshida, Teruhiko
AU - Waikar, Sushrut S.
AU - Ilori, Titilayo O.
AU - Wang, Guoying
AU - Rebuck, Heather
AU - Pearson, Colleen
AU - Wang, Mei Cheng
AU - Winkler, Cheryl A.
AU - Kopp, Jeffrey B.
AU - Wang, Xiaobin
N1 - Publisher Copyright:
© 2023 The Authors.
PY - 2023/11/21
Y1 - 2023/11/21
N2 - BACKGROUND: Pregnancy complications are risk factors for cardiovascular disease (CVD). Little is known about the role of renal biomarkers measured shortly after delivery, individually or in combination with pregnancy complications, in predicting subsequent severe maternal CVD. METHODS AND RESULTS: This study included 566 mothers of diverse races and ethnicities from the Boston Birth cohort, enrolled at delivery and followed prospectively. Plasma creatinine and CysC (cystatin C) were measured 1 to 3 days after delivery. CVD during follow-up was defined by physician diagnoses in electronic medical records. Associations of renal biomarkers and pregnancy complications with time-to-CVD events were assessed using Cox proportional hazards models. During an average of 10.3±3.2 years of follow-up, 30 mothers developed 1 or more CVDs. Only a modest association was observed between cre-atinine and risk of CVD. In comparison, we found that per 0.1 mg/L increase of CysC was associated with a hazard ratio (HR) of 1.2 (95% CI, 1.1–1.4) for CVD after adjusting for covariates. Compared with those without preeclampsia and with normal CysC level (≤75th percentile), mothers with preeclampsia and elevated CysC (>75th percentile) had the highest risk of CVD (HR, 4.6 [95% CI, 1.7–17.7]), whereas mothers with preeclampsia only or with elevated CysC only did not have significantly increased CVD risk. Similar synergistic effects for CVD were observed between CysC and preterm delivery. CONCLUSIONS: In this sample of US, traditionally underrepresented multiracial and multiethnic high-risk mothers, elevated maternal plasma CysC, independently and jointly with pregnancy complications, increased risk of CVD later in life. These findings warrant further investigation.
AB - BACKGROUND: Pregnancy complications are risk factors for cardiovascular disease (CVD). Little is known about the role of renal biomarkers measured shortly after delivery, individually or in combination with pregnancy complications, in predicting subsequent severe maternal CVD. METHODS AND RESULTS: This study included 566 mothers of diverse races and ethnicities from the Boston Birth cohort, enrolled at delivery and followed prospectively. Plasma creatinine and CysC (cystatin C) were measured 1 to 3 days after delivery. CVD during follow-up was defined by physician diagnoses in electronic medical records. Associations of renal biomarkers and pregnancy complications with time-to-CVD events were assessed using Cox proportional hazards models. During an average of 10.3±3.2 years of follow-up, 30 mothers developed 1 or more CVDs. Only a modest association was observed between cre-atinine and risk of CVD. In comparison, we found that per 0.1 mg/L increase of CysC was associated with a hazard ratio (HR) of 1.2 (95% CI, 1.1–1.4) for CVD after adjusting for covariates. Compared with those without preeclampsia and with normal CysC level (≤75th percentile), mothers with preeclampsia and elevated CysC (>75th percentile) had the highest risk of CVD (HR, 4.6 [95% CI, 1.7–17.7]), whereas mothers with preeclampsia only or with elevated CysC only did not have significantly increased CVD risk. Similar synergistic effects for CVD were observed between CysC and preterm delivery. CONCLUSIONS: In this sample of US, traditionally underrepresented multiracial and multiethnic high-risk mothers, elevated maternal plasma CysC, independently and jointly with pregnancy complications, increased risk of CVD later in life. These findings warrant further investigation.
KW - cardiovascular disease
KW - creatinine
KW - cystatin C
KW - preeclampsia
KW - pregnancy complication
UR - http://www.scopus.com/inward/record.url?scp=85178447037&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85178447037&partnerID=8YFLogxK
U2 - 10.1161/JAHA.122.029311
DO - 10.1161/JAHA.122.029311
M3 - Article
C2 - 37947096
AN - SCOPUS:85178447037
SN - 2047-9980
VL - 12
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
IS - 22
M1 - e029311
ER -